CTRI/2017/07/009118已完成未知
A multicenter, open label, randomized, two-treatment, two-period, two-sequence, single dose, cross-over bioequivalence study of Doxorubicin Hydrochloride (Pegylated liposomal) of Dr. Reddyâ??s Laboratories Ltd, India, with that of Caelyx® [Doxorubicin Hydrochloride (Pegylated Liposomal)] of Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium in advanced ovarian cancer and/or metastatic breast cancer patients under fed condition - NA
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 85
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Females of age between 18-65 years (both inclusive).
- •2. Able to understand the investigational nature of this study and
- •give written informed consent prior to the participation in the
- •3. Subject with advanced ovarian cancer requiring Doxorubicin
- •and who have failed a first-line platinum-based chemotherapy
- •regimen (Disease progression / reoccurrence after platinum
- •based chemotherapy).
- •As monotherapy for subjects with metastatic breast cancer
- •4. Cardiac function (left ventricular ejection fraction [LVEF]
- •5. Subject should have recovered from any toxic effects of
- •previous chemotherapy as judged by the Investigator.
- •6. Subject with life expectancy of at least 3 months.
- •7. Able to comply with study requirement in opinion of Principal
- •Investigator.
- •bin <= 1.5 Ã? ULN
- •8. Adequate recovery from recent surgery. At least 1 week must have elapsed from the time of minor surgery; at least 4 weeks must have elapsed from the time of major surgery.
- •9. Sexually active women, unless surgically sterile (at least 6 months prior to Study drug administration) or postmenopausal for at least 12 consecutive months, must have negative
- •pregnancy test at screening as well as prior to check-in and must agree to use an effective method of avoiding pregnancy (including oral, transdermal or implanted contraceptives [any
- •hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom
- •with spermicide by sexual partner or sterile [at least 6 months prior to Study drug administration] sexual partner) for at least 4
- •weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
- •It is investigatorâ??s responsibility to ensure that above points regarding an effective method of avoiding pregnancy are discussed with subject in detail and subject agreed for this and it is documented in source document. The investigator should ensure that the subject is using an effective method of avoiding pregnancy as per protocol.
排除标准
- •1. Subjects who are pregnant or breast feeding.
- •2. Subjects with an ECOG (Eastern Cooperative Oncology group) Performance Status Score > 3.
- •3. Subject who had received prior treatment with any liposomal doxorubicin injection.
- •4. If total cumulative dose of Doxorubicin HCl approaches 450 mg/m2.
- •5. Active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, P.carinii or other microorganism if under treatment with myelotoxic drugs.
- •6. Any other clinically significant liver or kidney disorders other than mentioned in the selection criteria.
- •7. Impaired cardiac function including any of the following conditions within past 6 months:
- •a. Unstable angina.
- •b. QTc prolongation or other significant ECG
- •abnormalities.
- •c. Coronary artery bypass graft surgery.
- •d. Symptomatic peripheral vascular disease.
- •e. Myocardial infarction.
- •f. NYHA class II-IV heart failure.
- •g. Severe uncontrolled ventricular arrhythmias.
- •h. Clinically significant pericardial disease.
- •i. Electrocardiographic evidence of acute ischemic or active conduction system abnormalities.
- •j. Subjects with evidence of abnormal cardiac conduction (e.g., bundle branch block or heart block) are eligible if their disease has been stable for the past six months.
- •k. Severe uncontrolled arrhythmias.
- •8. History of hypersensitivity reactions attributed to a conventional formulation of Doxorubicin Hydrochloride or the components
- •of Doxorubicin Hydrochloride Liposome (Pegylated Liposomal).
- •9. Use of any recreational drugs or history of drug addiction.
- •10. Known brain metastasis.
- •11. Pre-existing motor or sensory neurotoxicity of a severity >= grade 2 by NCI criteria.
- •12. Other serious illness or medical condition that would prohibit the understanding and giving of informed consent.
- •13. A positive hepatitis screen including hepatitis B surface antigen, HCV and HAV antibodies.
- •14. A positive test result for HIV antibody and/or syphilis (VDRL).
- •15. The receipt of an investigational product, or participation in a drug research study within a period of 90 days prior to the first
- •dose of investigational Product.
- •16. Any other condition that, in the investigatorâ??s judgment, might
- •increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
- •17. Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints.
- •18. Current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness,
- •any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures.
- •19. History of donation of blood/loss of blood (without replenishment) (1 unit or 350 ml) within 90 days prior to receiving the first dose of investigational medicinal product in
- •20. Uncontrolled hypertension (systolic blood pressure [BP] >160 or diastolic BP >100mm Hg) or uncontrolled cardiac arrhythmias (Subjects with hypertension controlled by antihypertensive therapies are eligible).
- •21. History of cerebrovascular accident (CVA), MI within 6 months or venous thrombosis within 12 w
研究者
相似试验
已完成
不适用
Bioequivalence study ofDoxorubicin Hydrochloride (Pegylated liposomal concentrate for solution for infusion 20 mg/10mL (2 mg/ml) in advanced ovarian cancer.CTRI/2015/10/006241Dr Reddys Laboratories Limited65
招募中
不适用
To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulationsCTRI/2012/08/002940Hetero Labs Ltd64
已完成
不适用
To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations.CTRI/2012/07/002778Hetero Labs Ltd64
已完成
不适用
A Clinical Trial to study the clinical bioequivalence of Clozapine 100 mg tablet of Aurobindo in comparison to Clozaril® (Clozapine) 100 mg tablet of Novartis in patients suffering from SchizophreniaCTRI/2013/06/003745Aurobindo Pharma Limited36
尚未招募
不适用
A study to compare absorption of the test drug - Tab Felbamate 600 mg with that of the approved drug - Tablet Felbatol (Felbamate 600,in patients of partial epilepsy not responding to therapy.CTRI/2014/05/004600annett Company Inc38